<DOC>
	<DOCNO>NCT02259517</DOCNO>
	<brief_summary>Children Attention-Deficit/Hyperactivity Disorder ( ADHD ) typically treat two type medication differ mechanisms action : stimulant non-stimulants . The stimulant Vyvanse ( lisdexamfetamine , LDX ) , non-stimulant Intuniv ( extended-release guanfacine , GXR ) , FDA approve treatment ADHD . Clinical trial show medication effective reduce ADHD symptom , although neurobiological mechanism Vyvanse Intuniv produce effect remain unknown . The aim study examine mechanism LDX GXR reduce symptom patient ADHD . MRI scan use identify treatment-related change brain structure function .</brief_summary>
	<brief_title>An fMRI Study Stimulant vs. Non-Stimulant Treatment ADHD</brief_title>
	<detailed_description>Children ADHD age sex-matched healthy control scan begin study . In first part study , MRI finding compare two group see whether brain functioning child ADHD differs healthy child . In second part study , child ADHD meet weekly study doctor administer either extended-release guanfacine ( Intuniv ) lisdexamfetamine ( Vyvanse ) 6 week . Selection either treatment group randomly determine . At end study , child ADHD treat either medication second MRI scan . The finding second MRI scan compare first MRI scan order examine brain change due medication . These second MRI scan also compare scan healthy control .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>ADHD Participants : The participant satisfy Diagnostic Statistical Manual Mental Disorders ( DSM ) criteria primary diagnosis ADHD , subtype . Healthy Control Participants : The participant must current DSM Axis I psychiatric disorder . All Participants : Participants must provide assent legal guardian must provide consent . The participant male female 6 17 year age . Girls childbearing potential must negative urine pregnancy test , sexually active , must use adequate contraception . The participant English speaking . ADHD Participants : The participant current comorbid DSM Axis I psychiatric diagnosis symptomatic manifestation , opinion study doctor , contraindicate guanfacine treatment confound safety assessment . The participant meet DSM criterion current substance abuse and/or dependence . The participant currently take , take within past 4 month , psychotropic medication . The participant document allergy intolerance guanfacine product . The participant diagnosis history cardiovascular disease serious medical illness . The participant pregnant lactating . The participant actively suicidal . MRI contraindication ( e.g. , irremovable metal body , pacemaker , brace ) The participant full scale intelligence quotient ( IQ ) less 70 . Healthy Controls : The participant meet DSM criterion current substance abuse and/or dependence . The participant currently take psychotropic medication . The participant history serious medical illness . The participant pregnant lactating . MRI contraindication ( e.g. , irremovable metal body , pacemaker , brace ) The participant full scale intelligence quotient ( IQ ) less 70 .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Intuniv</keyword>
	<keyword>Non-stimulant</keyword>
	<keyword>Guanfacine extended-release</keyword>
	<keyword>Vyvanse</keyword>
	<keyword>Stimulant</keyword>
	<keyword>Lisdexamfetamine</keyword>
</DOC>